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Introduction
------------

Cost-of-Illness (COI) studies aim to identify and measure all the costs of a disease \[[@B1]\]. They describe and estimate the economic burden of a specific disease to a society, and therefore the savings that could be done if the disease were to be eradicated \[[@B2]\]. COI studies as decision making tool has been debated, but they may be useful by educating, informing and enlightening policy makers in planning and financing \[[@B3]\]. COI studies are particularly relevant in chronic diseases that weigh heavily on health expenditures. Dementia is characterized by a gradual and irreversible impairment of the intellect, memory, and personality. Alzheimer disease (AD) accounts for 60% to 80% of all dementia cases and its prevalence will increase with the life expectancy growth \[[@B4]\]. There are 35, 6 million demented people in 2011, increasing to 115,4 million by 2050 \[[@B5]\]. Disease worldwide costs were US\$ 604 billion in 2011, which 84% were attributable to informal and formal costs. COI studies are the initial step in an economic evaluation. Few cost-effectiveness analyses in AD drug treatment show divergent results in costs saving \[[@B6],[@B7]\], probably because of different methodologies. So, it is necessary to accurately assess AD costs to show the potential economic impact of new therapeutic or preventive strategies. Three articles were previously published on the methodology of AD costs \[[@B8]-[@B10]\], but they were either focus on European studies including other dementia (not on AD specifically), or focus on informal costs and not focus on COI studies. This study aims to review relevant published AD COI studies, to analyze the methods used and to identify the points that should be improved in order to obtain convincing results from a methodological perspective. First, we provided a general description of the COI method. And then, we systematically reviewed AD costs studies, analyzing the different methods used.

Methods
-------

### Cost study

To conduct a COI study, it is necessary to define disease, epidemiological approach, type of costs, and study perspective. Subsequently, resource consumption data and unit costs can be gathered, and the results presented and methodically discussed, in conjunction with sensitivity analysis to test their robustness. A checklist (Table  [1](#T1){ref-type="table"}), containing its items, was developped on the model described by Drummond et al. \[[@B11]\] and adapted to COI by Molinier et al. \[[@B12]\]. An equal weight was given to each item. The final score was the sum of the eleven individual items.

###### 

Answers to the methodological questions by study

                                                                                        **All studies**   **Lopez Bastida et al.**\[[@B13]\]   **Coduras et al.**\[[@B14]\]   **Rigaud et al.**\[[@B15]\]   **Kronborg Andersen et al.**\[[@B16]\]   **Cavallo et al.**\[[@B17]\]   **Mesterton et al.**\[[@B18]\]   **Kiencke et al.**\[[@B19]\]   **Leon et al.**\[[@B20]\]   **Hay et al.**\[[@B21]\]   **Rice et al.**\[[@B22]\]   **Leon et al.**\[[@B23]\]   **Ostbye et al.**\[[@B24]\]   **Zencir et al.**\[[@B25]\]   **Wang et al.**\[[@B26]\]   **Suh et al.**\[[@B27]\]   **Beeri et al.**\[[@B28]\]   **Allegri et al.**\[[@B29]\]                                                                                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------ ----------------- ------------------------------------ ------------------------------ ----------------------------- ---------------------------------------- ------------------------------ -------------------------------- ------------------------------ --------------------------- -------------------------- --------------------------- --------------------------- ----------------------------- ----------------------------- --------------------------- -------------------------- ---------------------------- ------------------------------ --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- -------- --------- ------- --------
                                                                                            **Yes**                     **P**                             **No**                        **Yes**                             **P**                               **No**                         **Yes**                          **P**                        **No**                     **Yes**                      **P**                      **No**                       **Yes**                        **P**                       **No**                     **Yes**                      **P**                         **No**              **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**   **Yes**   **P**   **No**
  1 Was a clear definition of the illness given?                                              10                          5                                 2                                                                 P                                                                  Yes                                                                                      Yes                                                                                  Yes                                                                                                                                              No                            P                          P                Yes                                          No                 P                Yes                        Yes                        Yes                        Yes                                  P                Yes                        Yes                
  2 Were epidemiological sources carefully described?                                         13                          3                                 1                             Yes                                                                                                    Yes                                                                                      Yes                                                                                  Yes                                                                                   Yes                                                                                      P                Yes                        Yes                        Yes                        Yes                                  P                Yes                                  P                Yes                        Yes                                          No       Yes                
  3 Were costs sufficiently disaggregated ?                                                   12                          0                                 5                             Yes                                                                                                    Yes                                                                                                                                              No                           Yes                                                                                   Yes                                                                            Yes                        Yes                                          No       Yes                        Yes                                          No                         No       Yes                        Yes                                          No       Yes                        Yes                
  4 Were activity data sources carefully described?                                           15                          1                                 1                             Yes                                                                                                    Yes                                                                                      Yes                                                                                  Yes                                                                                   Yes                                                                            Yes                                  P                Yes                        Yes                        Yes                        Yes                                          No       Yes                        Yes                        Yes                        Yes                        Yes                
  5 Were activity data appropriately assessed?                                                 6                          9                                 2                             Yes                                                                                                                                     P                                                                                    P                                                                                      P                                                                                   P                                                 Yes                                          No       Yes                        Yes                        Yes                                  P                                  No                 P                          P                Yes                                  P                          P        
  6 Were the sources of all cost values analytically described?                               10                          4                                 3                             Yes                                                                                                    Yes                                                                                      Yes                                                                                  Yes                                                                                                                P                                                 Yes                                          No       Yes                        Yes                                  P                          P                                  No                 P                Yes                        Yes                                          No       Yes                
  7 Were unit costs appropriately valued?                                                      7                          5                                 5                             Yes                                                                                                    Yes                                                                                                                   P                                                                                      P                                                                                   P                                                 Yes                                          No       Yes                        Yes                                  P                                  No                         No                         No       Yes                        Yes                                          No                 P        
  8 Were the methods adopted carefully explained?                                             11                          6                                 0                             Yes                                                                                                    Yes                                                                                      Yes                                                                                  Yes                                                                                                                P                                                 Yes                                  P                Yes                        Yes                                  P                          P                          P                Yes                        Yes                        Yes                                  P                Yes                
  9 Were costs discounted ?                                                                    0                          2                                 15                                                                                                    No                                                                                           No                                                                                 No                                                                                      No                                                                                    No                                    No                 P                                  No                 P                                  No                         No                         No                         No                         No                         No                         No                         No
  10 Were the major assumptions tested in a sensitivity analysis?                              3                          0                                 14                                                                                                    No                             Yes                                                                                                                                              No                                                                                      No                                                                                    No                                    No       Yes                                          No                         No                         No                         No                         No                         No                         No       Yes                                          No                         No
  11 Was the presentation of study results consistent with the methodology of study?          13                          4                                 0                             Yes                                                                                                    Yes                                                                                      Yes                                                                                  Yes                                                                                   Yes                                                                            Yes                        Yes                                  P                          P                Yes                        Yes                                  P                Yes                        Yes                        Yes                                  P                Yes                
  12 Total score by study                                                                     100                         39                                48                             8                                  1                                   2                               9                               1                             1                          6                           2                           3                            7                             2                            2                          4                           4                             3                    7        2       2         4        4       3         7        1       3         7        2       2         5        4       2         3        4       4         2        2       7         5        3       3         8        1       2         8        1       2         3        3       5         7        2       2

Total score by study was the sum of answers; P, Partially.

### Defining the disease and population

Illness costs widely depend on how the disease is defined. AD diagnosis is based on Alzheimer's Association criteria (NINCDS-ADRDA) \[[@B30]\] and Diagnostic and Statistical Manual of Mental Disorders criteria (DSM IV) \[[@B31]\]. As costs increase with disease severity \[[@B32]-[@B35]\], disease stage must be specified and measured using validated tools, as Clinical Dementia Rate \[[@B36]\] (CDR) or Mini Mental State Examination (MMSE) \[[@B37]\]. Cost components may vary depending on the living conditions (e.g. home, institution), and therefore must be specified \[[@B33],[@B38]\].

### Epidemiological approach

Prevalence-based COI studies estimate the economic burden to society during a period of time as a result of the prevalence of the disease (e.g. in a given year). Incidence-based studies estimate lifetime costs, and measure the costs of an illness from diagnosis until recovery or another endpoint (e.g. death).

### Perspective of the analysis and costs assessed

A COI study may be conducted from several perspectives that must be specified to check that relevant costs are included. From the healthcare payer perspective, only direct costs incurred by a payer (e.g. national health insurance) are considered. Indirect costs and the patient "out-of-pocket" must also be included in a study which uses societal perspective.

### Estimating resource consumption

Resource consumption estimates vary depending on the data available, but validated tools exist to collect them \[[@B39]\]. In prospective COI studies, events have not occurred yet, so data collection is done by the patients' follow-up, medical records, data from clinical trials and patients or caregiver questionnaires. Conversely, in retrospective COI study, events have already occurred, so data collection must refer to recorded data, either using "Top-down" method (aggregate figures from hospital admissions, mortality, etc.) or "bottom-up" method (by referring to the patients sample record).

### Valuation of unit costs

The COI is estimated by identifying the cost-generating components and by attributing them a monetary value. This is the opportunity cost, the value of the forgone opportunity to use in a different way those resources that are lost due to illness \[[@B11]\]. Direct and indirect costs should be valued to assess the total economic COI. Direct costs measure the resources used to treat an illness and can be estimated by per capita expenditures, national tariffs, market prices, and published studies. Patient charges and tariffs do not give an accurate estimate of the underlying costs. Market prices can be used to value some cost categories like drugs, rehabilitation items (e.g. eyeglasses, etc.). Direct costs can also be valued with care facilities estimates, through the analytical account system which specified distribution properties. Indirect costs measure the loss of productivity, the effect of the illness on the patient or caregiver abilities to work. Three methods are used to value indirect costs: the Human Capital Approach (HCA) \[[@B40]\], the Friction Cost Method \[[@B41]\] and the Willingness to pay approach \[[@B42]\]. Informal care is an unpaid care often provided by relatives and plays a substantial role in the AD patient's total care. Two methods are mainly used to value the shadow price of informal care time. The opportunity cost approach values the opportunity forgone as a result of caregiving and the replacement cost approach values the caregiving time spent at a price of a close substitute \[[@B9],[@B43],[@B44]\].

### Discounting costs

Discounting captures individual preferences for income today rather than income in the future and is frequently applied when COI studies are considered over several years. In the USA, they estimate the discount rate at 3% \[[@B45]\]. The following equation is applied to estimate costs:

$$C_{a} = C_{t}{\sum\limits_{n = 1}^{t}\left( {1 + r} \right)}^{- n}$$

Where: *C*~*a*~ = present value of cost strategy, *C*~*t*~ = value of cost strategy in year t, r = discount rate, t = time period.

### Sensitivity analysis

Sensitivity analysis is recommended because COI studies contain uncertainties. It allows testing the robustness of the results by varying in range key variables (e.g., prevalence, unit costs, etc.) \[[@B46]\]. It seems more credible to present a range of possible illness costs.

### Presentation of results

The presentation of COI results should be consistent with collected data and should disaggregate results into as many components as possible with full explanations given for clarity (Table  [1](#T1){ref-type="table"}).

### Literature review

#### Study selection

A bibliographic search was performed on an international medical literature database (Medline). All studies which assessed the economic burden of AD were selected. To be exhaustive, eight keywords combinations were employed: "Alzheimer disease" AND "Cost of illness"; "Alzheimer disease" AND "Economic evaluation"; "Alzheimer disease" AND "Cost study"; "Alzheimer disease" AND "Cost analysis"; "Dementia" AND "Cost of illness"; "Dementia" AND "Economic evaluation"; "Dementia" AND "Cost study"; "Dementia" AND "Cost analysis". This search provided us 2271 papers. We kept the 2033 papers written in English. Among them, we selected articles whose title contained "Dementia" *or* "Alzheimer disease" (801 papers were removed) AND "Costs" *or* "Expenses" *or* "Economic" *or* "Burden" (another 941 papers were removed). This study focused on the methodology used to estimate AD costs, 137 papers were removed because they were identified as global economic analyses. A hundred and fifty four abstracts were first selected and 46 of them underwent a subsequent full paper reading, thus providing 17 articles. Figure  [1](#F1){ref-type="fig"} illustrates the literature search, selection process, and presents reasons for excluded studies.

![Literature search and selection process.](2191-1991-2-18-1){#F1}

#### Study review

A systematic review was performed. One author (N. Costa) selected abstracts. Six methodologists read the 46 papers retrieved by the search strategy and reviewed the 17 selected papers. With the key methodological points identified in the first part of the paper, they asked questions based on existing checklists for full economic evaluations \[[@B47]\]. The objective was not to establish a criteria hierarchy by using different weights, but to use these criteria to analyze the methods used. Each study was assessed separately by the reviewers. Finally, a consensus was reached by discussion. Then, all authors, both clinicians and methodologists, discussed the results.

Results
-------

Seventeen studies met our criteria (Tables  [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Seven studies were conducted in Europe \[[@B13]-[@B19]\], 5 in North America \[[@B20]-[@B24]\], 4 in Asia \[[@B25]-[@B28]\] and 1 in South America \[[@B29]\]. Fifteen studies selected a sample ranging in size from 42 to 21512 patients \[[@B13]-[@B20],[@B22]-[@B29]\].

###### 

Cost of illness studie\'s characteristics in Alzheimer disease

  **Study**                              **Country**   **Type of helthcare system (insurance)**   **Year of valuation**   **Currency**   **Perspective**    **Design of cost analysis**   **Sample size**      **Type of setting**       **Follow-up (months)**   ***Total annual cost per patient (US\$)***
  ------------------------------------- ------------- ------------------------------------------ ----------------------- -------------- ------------------ ----------------------------- ----------------- ---------------------------- ------------------------ --------------------------------------------
  Lopez Bastida et al. \[[@B13]\]           Spain                   Public social                         2001                 €             Societal              Prosepective                 237                  At home                       12                            ***37,881***
  Coduras et al. \[[@B14]\]                 Spain                   Public social                         2006                 €             Societal         Prospective multicentre           560         At home and in institution             12                            ***22,558***
  Rigaud et al. \[[@B15]\]                 France                   Public social                         1996                 €             Societal       Retrospective single centre         48                   At home                       6                             ***31,153***
  Kronborg Andersen et al. \[[@B16]\]      Denmark                  Public social                         1997                DKK            Societal        Prospective single centre          164         At home and in institution             12                            ***17,078***
  Cavallo et al. \[[@B17]\]                 Italy                 Public and private                      1995                 ₤              Family         Prospective single centre          423                  At home                       NS                            ***52,954***
  Mesterton et al. \[[@B18]\]              Sweden                   Public social                         2007                SEK            Societal         Prospective multicentre           233         At home and in institution             1                             ***46,956***
  Kiencke et al. \[[@B19]\]                Germany                  Public health                         2005                 €         Healthcare payer         Decision model               21512                    NS                         60                            ***11,786***
  Leon et al. \[[@B20]\]                     USA                       Private                            1996                US\$           Societal         Prospective multicentre           150         At home and in institution             1                             ***18,804***
  Hay et al. \[[@B21]\]                      USA                       Private                            1983                US\$           Societal              Retrospective                NS          At home and in institution          Lifetime                        ***18,517\****
  Rice et al. \[[@B22]\]                     USA                       Private                            1990                US\$           Societal         Prospective multicentre           187         At home and in institution             12                           ***51,905\****
  Leon et al. \[[@B23]\]                     USA                       Private                            1996                US\$           Societal         Prospective multicentre           679         At home and in institution             NS                            ***27,672***
  Ostbye et al. \[[@B24]\]                 Canada                   Public social                         1991               CAN\$           Societal               Not specify                10263        At home and in institution             NS                           ***13,900\****
  Zencir et al. \[[@B25]\]                 Turkey                 Public and private                      2003                TRY               NS                 Prosepective                 42                   At home                       3                             ***3,492***
  Wang et al. \[[@B26]\]                    China              Public social insurance                    2006                RMB               NS           Prospective single centre          66                      NS                         12                           ***2,935\****
  Suh et al. \[[@B27]\]                     Korea                      Private                            2002                 ₩             Societal             Decision model                NS          At home and in institution             12                            ***11,389***
  Beeri et al. \[[@B28]\]                  Israel                   Public social                         1999                NIS            Societal         Prospective multicentre           121         At home and in institution             6                            ***19,893\****
  Allegri et al. \[[@B29]\]               Argentina               Public and private                      2001                \$Ar           Societal              Retrospective                100         At home and in institution             3                             ***7,709***

NS: not specify; NA: not available, \* Net Costs.

All costs are in US\$ (1€ = 1,36491 US\$, 1 CAN\$ = 0,970458 US\$, 1 DKK = 0,183360 US\$, 1 RMB = 0,156987 US\$; October 11, 2011) SEK, Swedish Crown; RMB, Yuan Renminbi; ₩, Won; \$Ar, Argentine Peso; NIS, New Israeli Shekel; TRI, Turkish Lira; CAN\$, Canadian Dollar; DKK, Danish Crown; €, Euro).

###### 

Total annual costs disaggregation

  **Study**                              ***Total annual cost per patient (US\$)***   **Direct medical costs**   **Inpatient**   **Outpatient**   **Medication**   **Specialized institution**   **Other**   **Direct non medical costs**   **Home help**   **Nursing home**   **Transportation**   **Other**   **Informal costs**   **Indirect costs**
  ------------------------------------- -------------------------------------------- -------------------------- --------------- ---------------- ---------------- ----------------------------- ----------- ------------------------------ --------------- ------------------ -------------------- ----------- -------------------- --------------------
  Lopez Bastida et al. \[[@B13]\]                       ***37,881***                         **4,848**                924             844             2,468                    301                  311               **2,306**                 2,223              NA                  83              NA           **29,884**            **843**
  Coduras et al. \[[@B14]\]                             ***22,558***                         **4,744**                144             503             2,137                   1,97                  NA                **5,798**                 4,66             1,138                 NA              NA           **12,016**             **NA**
  Rigaud et al. \[[@B15]\]                              ***31,153***                         **6,663**                NS               NS               NS                     NS                   NA                **5,632**                 5,632              NS                  NS              NA           **18,858**             **NA**
  Kronborg Andersen et al. \[[@B16]\]                   ***17,078***                         **4,357**               4,11             247               NA                     NA                   NA                **12,721**               12,663              NA                  NA              58             **NA**               **NA**
  Cavallo et al. \[[@B17]\]                             ***52,954***                         **2,722**                NA               NA               NA                    2,722                 NA                **5,496**                 5,496              NA                  NA              NA           **44,736**             **NA**
  Mesterton et al. \[[@B18]\]                           ***46,956***                         **3,155**               1,067           1,118             970                     NA                   NA                **39,373**                6,487            32,886                NA              NA           **4,428**              **NA**
  Kiencke et al. \[[@B19]\]                             ***11,786***                         **11,786**              2,889           1,449            2,126                    NS                   677                 **NA**                   NA                NA                  NA              NA             **NA**               **NA**
  Leon et al. \[[@B20]\]                                ***18,804***                         **7,284**                NS               NS               NS                     NA                   NA                  **NA**                   NA                NA                  NA              NA           **11,52**              **NA**
  Hay et al. \[[@B21]\]                                ***18,517\****                        **2,292**                756            1,292             244                     NA                   NA                **7,285**                 1,774            5,326                167              18             **9**                **NA**
  Rice et al. \[[@B22]\]                               ***51,905\****                        **22,176**              1,072            545              301                   19,521                 737               **9,699**                 9,585              NA                  NA              114          **20,03**              **NA**
  Leon et al. \[[@B23]\]                                ***27,672***                         **21,924**               NS               NS               NS                     NS                   NS                  **NA**                   NA                NA                  NA              NA           **5,748**              **NA**
  Ostbye et al. \[[@B24]\]                             ***13,900\****                          **NS**                 NS               NS               NS                     NS                   NS                  **NS**                   NS                NS                  NA              NS             **NS**               **NA**
  Zencir et al. \[[@B25]\]                              ***3,492***                          **2,128**                NA               37              2091                    NA                   NA                  **NA**                   NA                NA                  NA              NA           **1,364**              **NA**
  Wang et al. \[[@B26]\]                               ***2,935\****                          **863**                 29               32              802                     NA                   11                 **431**                   373               NA                  NA              27            **1,63**              **NA**
  Suh et al. \[[@B27]\]                                 ***11,389***                         **4,394**                NS               NS               NS                     NA                   NA                 **445**                   445               NA                  NA              NA            **6,55**              **NA**
  Beeri et al. \[[@B28]\]                              ***19,893\****                        **3,974**               1,749            1,63             584                     NA                   11                **9,326**                 1,822            7,504                 NA              NA           **6,593**              **NA**
  Allegri et al. \[[@B29]\]                             ***7,709***                          **3,389**                525             280             2,389                    NA                   195               **2,488**                  187             2,301                 NA              NA           **1,832**              **NA**

NS: not specify; NA: not available, \* Net Costs.

All costs are in US\$ (1€ = 1,36491 US\$, 1 CAN\$ = 0,970458 US\$, 1 DKK = 0,183360 US\$, 1 RMB = 0,156987 US\$; October 11, 2011).

SEK, Swedish Crown; RMB, Yuan Renminbi; ₩, Won; \$Ar, Argentine Peso; NIS, New Israeli Shekel; TRI, Turkish Lira; CAN\$, Canadian Dollar; DKK, Danish Crown; €, Euro).

Defining the disease and population
-----------------------------------

AD was defined with NINCDS-ADRDA criteria for 4 studies \[[@B20],[@B23],[@B28],[@B29]\], with DSM criteria for 2 studies \[[@B25],[@B26]\], with both criteria for 4 studies \[[@B14]-[@B16],[@B24]\] and with ICD-10 for another study \[[@B19]\]. Six studies did not specify the criteria used \[[@B13],[@B17],[@B18],[@B21],[@B22],[@B27]\]. Disease severity was measured with MMSE in 9 studies \[[@B14],[@B15],[@B18],[@B22],[@B24]-[@B28]\], with CDR in 3 studies \[[@B13],[@B16],[@B23]\], and with both tests for 2 studies \[[@B20],[@B29]\]. Disease severity was not specified in three studies \[[@B17],[@B21],[@B23]\]. Four studies included community dwelling patients \[[@B13],[@B15],[@B17],[@B25]\] and 11 studies included both patients in community and in institution \[[@B14],[@B16],[@B18],[@B20]-[@B24],[@B27]-[@B29]\]. The place of living was not specified in 2 studies \[[@B19],[@B26]\].

Thirteen studies specified the mean age of the sample of patients ranging from 70,5 to 81,8 years \[[@B13]-[@B20],[@B22],[@B25],[@B26],[@B28],[@B29]\].Two studies included patients aged from 50 to over 80 years \[[@B21],[@B24]\].

### Perspective of the analysis and costs assessed

The adopted perspective was the society in 13 studies \[[@B13]-[@B16],[@B18],[@B20]-[@B24],[@B27]-[@B29]\] and respectively the family and the healthcare payer in two studies \[[@B17],[@B19]\]. Fourteen studies quantified direct medical and non-medical costs and informal costs \[[@B14],[@B15],[@B17],[@B18],[@B20]-[@B29]\]. Two studies did not include inpatient costs \[[@B17],[@B25]\]. Informal costs were defined as direct non-medical costs in seven studies \[[@B14],[@B15],[@B17],[@B19],[@B22],[@B23],[@B25]\] and as indirect costs in seven studies \[[@B18],[@B21],[@B24],[@B26]-[@B29]\]. One study quantified all the costs (i.e. direct, informal and indirect) \[[@B13]\], indirect costs were defined as patient early retirement and informal costs as direct non-medical costs. Danish study quantified only direct medical and non-medical costs \[[@B16]\]. German study quantified only direct medical costs \[[@B19]\].

### Estimating resource consumption

Three studies estimated resource consumption retrospectively \[[@B15],[@B21],[@B29]\]. Two of them used bottom-up approach to gather activity data through questionnaires \[[@B15],[@B29]\]. The other used a top-down approach, using published national indicators, national surveys and published studies \[[@B21]\]. Eleven studies estimated resource consumption prospectively \[[@B13],[@B14],[@B16]-[@B18],[@B20],[@B22]-[@B24],[@B26],[@B28]\]. Two studies used mainly the Resource Utilisation in Dementia (RUD) \[[@B48]\] to gather activity data \[[@B14],[@B18]\], completed with report forms, medical records and questionnaires on 560 patients in the Spanish study \[[@B14]\]. Nine studies gathered activity data mainly with questionnaires \[[@B13],[@B16],[@B17],[@B20],[@B22],[@B23],[@B25],[@B26],[@B28]\]. In the Danish study, 164 AD couple (i.e. patients/caregivers) was interviewed at home about Activities of Daily Living (ADL), use of health care and community services \[[@B16]\]. Two US studies measured direct costs using caregiver's interviews and Medicare Current Beneficiary Survey (MCBS) \[[@B13],[@B23]\]. Rice et al. gathered activity data through monthly caregiver's telephone interviews, billing records and with calendar given to caregiver at the baseline visit \[[@B23]\]. Israeli study used a baseline questionnaire to record time spent on caring and use of goods and services, and secondly recorded the same items with 5 monthly telephone interviews \[[@B28]\]. Two studies recorded data via mailed questionnaires filled out by caregivers \[[@B13],[@B17]\]. Turkish study used a questionnaire and daily time sheets for caregiving time \[[@B25]\]. Wang et al. interviewed 66 AD couples for filling out the resource use's questionnaire \[[@B26]\]. Two studies used decision modelling \[[@B19],[@B27]\] and estimated resources with published sources and national surveys \[[@B27]\] or with data extractions of a German retrospective analysis \[[@B19]\]. One study did not precise the approach used to gather activity data \[[@B24]\]. Eight studies specified the number of caregiver included, several for 4 studies \[[@B13],[@B15],[@B17],[@B22]\] and only one for others \[[@B18],[@B23],[@B25],[@B28]\]. Eight studies recorded AD net costs \[[@B15],[@B16],[@B21],[@B22],[@B24],[@B26],[@B28],[@B29]\] either by subtracting healthy patient costs or by asking AD couple about resource's used exclusively for AD.

The follow-up period was the lifetime in the study which adopted the incidence-based approach \[[@B21]\] and was one year in six studies \[[@B13],[@B14],[@B16],[@B22],[@B26],[@B27]\], but was frequently reduced to six, three or one month \[[@B14],[@B18],[@B20],[@B25],[@B28],[@B29]\]. One study used a sixty months follow-up period \[[@B19]\].

### Valuation of unit costs

Direct costs were estimated from published data, national estimates and Medicare-over charges in one American study \[[@B21]\], and from unit costs using the MCBS and national estimates for adult day care in another one \[[@B20]\]. Rice et al. used charges and bills provided by the caregivers \[[@B22]\]. Two Spanish studies used the Spanish database on medical costs (SOIKOS), patient's reports and the Spanish Vademecum to estimate unit costs \[[@B13],[@B14]\]. Direct unit costs were based on reimbursement tariffs used by the French social health insurance and on the French Disease related group (DRG) for inpatient care \[[@B15]\]. The Danish study used the reimbursement tariffs of social insurance, hospital accounts, gross wage rates of professionals and amortization procedure to value direct costs \[[@B16]\]. Institutional costs were valued with the average cost per day without food and beverage. Zencir et al. valued unit costs with the average price of public and private physician visits and with the average price per day for medication \[[@B25]\]. In the Chinese study, unit costs were valued with drugs prices, transportation reimbursements and local fees for home help \[[@B26]\]. Tariffs of social health insurance and full drugstore prices were used to unit costs valuation in the Argentinian study \[[@B28]\]. Meserton et al. valued unit costs with ward-specific per diem costs from regional price, the lowest available price for medication and with per visit costs \[[@B21]\]. For residential care, the number of days in institution was multiplied by the corresponding unit costs. Two studies used national estimates to value unit costs \[[@B23],[@B27]\]. No information relating to direct costs valuation was reported in four studies \[[@B17]-[@B19],[@B24]\]. Twelve studies used the replacement cost approach to value informal care \[[@B13],[@B15],[@B17],[@B20]-[@B26],[@B28],[@B29]\]. Seven studies used national estimates of a close substitute \[[@B17],[@B20]-[@B23],[@B25],[@B29]\]. Among these, 5 studies used different national wages to value different caregiver's activities \[[@B17],[@B20],[@B22],[@B23],[@B28]\]. Israeli study obtained different hourly wage rates for each activity from the Central Bureau of Statistics \[[@B28]\] and Leon et al. used hourly wage of home health aids to value ADL time and homemaker's hourly wage to value IADL time \[[@B23]\]. Two studies used hospital nurse hourly wage \[[@B21],[@B25]\], another one, local wage rate without specifying the type of professional caregiver \[[@B26]\] and the Canadian study used published data \[[@B24]\]. Three studies did not specify the sources used to value informal care time \[[@B13],[@B15],[@B29]\]. Nevertheless, one study used professional caregiver monthly salary \[[@B29]\], another the cost per hour of a domestic cleaner gross wage \[[@B13]\] and the last one the average between housekeeping and paid assistance wage \[[@B15]\]. One study chose opportunity cost approach to value informal care, using the mean informal caregiver own salary \[[@B14]\]. Both approaches were used in one study \[[@B27]\]. The time spent by working caregivers was valued with national estimates and the time spent by working caregivers was valued with the own caregivers salaries. Opportunity cost and revealed preference approaches were used to value informal costs in one study \[[@B18]\]. Caregiving time was valued either with the HCA (working caregivers) or with a monetary estimate value of one hour of leisure time (not working caregivers). One study valued indirect costs with national estimates on employment and wages \[[@B13]\].

### Discounting costs

One study has discounted costs without specifying the discounting rate \[[@B21]\]. German study performed costs discounting in the sensitivity analysis \[[@B19]\]. All the other studies used a short follow-up period and had no need to discount costs.

### Sensitivity analysis

Only three studies performed a sensitivity analysis \[[@B14],[@B27],[@B29]\]. One study analyzed the impact of informal costs variation \[[@B14]\], another one the variation of AD sufferers' proportion according to the need of full time care level \[[@B27]\], and the last one the discounting of the incurred costs \[[@B19]\].

### Presentation of results

Most studies presented their results clearly. They were mainly well explained and consistently set out in relation to the methods adopted. Five studies did not sufficiently disaggregate costs, so the information strength was reduced (Table  [3](#T3){ref-type="table"}) \[[@B15],[@B20],[@B23],[@B24],[@B27]\]. All studies presented results in terms of cost per patient. Four studies proposed also AD total costs for the country \[[@B13],[@B23],[@B24],[@B27]\]. According to the key methodological points, we have drafted a checklist of questions related to the eight items analyzed (Table  [1](#T1){ref-type="table"}). For 9 studies, the answers of at least seven to eleven questions were "yes" \[[@B13],[@B14],[@B16],[@B18],[@B20],[@B21],[@B26],[@B27],[@B29]\].

Conclusion
==========

This study reviewed seventeen COI studies on AD with the main goal of analyzing the various methodologies. According to the key methodological points, nine studies scored "yes" on the majority of the questions \[[@B13],[@B14],[@B16],[@B18],[@B19],[@B21],[@B26],[@B27],[@B29]\].

In this review, annual cost per patient varies from \$2,935 to \$52,954, confirming the costly character of AD. Nevertheless, commenting on these quantitative results is a problem because different approaches have been adopted. Informal care time varies widely according to the tool used. Validated instruments such as RUD, Caregiver Activity Survey (CAS) or Caregiver Activity Time Survey (CATS) exist to estimate informal care time \[[@B48]-[@B50]\]. Most often, time spent in ADL and IADL was used but they measure dependence and not specifically AD caregiving time. Opportunity cost underestimates the time of women, elderly and minority that suffer from discrimination in labour market \[[@B51]\], and does not allow the valuation of different informal caregiving activities. These activities change can be considered with the replacement cost approach. Informal costs vary with the number of caregiver included. Informal costs can be 8 times higher if several caregivers are included rather than just one. AD informal costs have to be rigorously quantified because they represent 36% to 85% of total costs \[[@B9]\].

Unlike clinical trial results, it is very difficult to generalize results of economic studies conducted in different countries. Economic results are difficult to compare because of monetary issues (i.e. fluctuating exchange rates, purchasing powers of currencies). According to the World Bank classification \[[@B52]\], 3 studies in this review were conducted in upper middle income economies \[[@B25],[@B26],[@B29]\] and presented a mean annual cost for an AD patients which is 5 times lower than in studies conducted in high income economies. Purchasing Power Parity (PPP) use could help results comparison because it eliminates price levels differences between countries \[[@B53]\].

Domestic characteristics also affect resource consumption and unit costs, including differences in clinical practice and healthcare system framework. For example, medication costs can vary between studies because of the use of tariffs in solidarity systems which are not comparable to free prices in private systems.

Follow-up periods found in this review were often less than one year, which is a short period to assess chronic disease costs. However, data collection over a long period is difficult so the use of models could compensate this difficulty.

Some limitations are present in this review as only English papers were selected, which restricted our sample. Another limitation is based on the lack of items weighting (Table  [1](#T1){ref-type="table"}). It is likely that results are more significantly affected by some items than others. Further works must be performed in this area.

Nevertheless, this study built an inventory on the methodology used to analyze AD costs and helped in better understanding the reasons of disparate results between studies.

COI results are the basis for economic evaluations and provide information for models that is a part of any efficiency evaluation \[[@B45]\]. Nevertheless, an insufficient description of methods may lead to misunderstandings. COI studies identified in this review highlight the poor consensus of methodological approaches. Medical journal should encourage researchers to give clear descriptions and discuss limitations, and a further effort should be made to validate methodology. The definition of standards, with a large consensus in the methodology selected to conduct this studies, should be a major concern for the scientific community. A collective awareness about disease burden exists between economists, policies and caregivers that may lead to relevant decision making. COI studies can serve as a basis for projecting disease expenses, and thus allow adapting medical and social disease management in order to control AD costs.
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